Potential therapies

Drug Development Pipeline for Myotonic Dystrophy Type 1 (DM1) and Myotonic Dystrophy Type 2 (DM2)

The Myotonic Dystrophy Foundation is now tracking the pipeline of potential therapies for Myotonic Dystrophy being developed by pharmaceutical companies. The table includes therapies in early laboratory development all the way up to early and late clinical development.

View the MDF Drug Development Pipeline here